Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post‐hoc analysis from the REWIND randomized trial
Authors:
- Kelley R.H. BranchKBKelley R.H. Branch
- Gilles R. DagenaisGDGilles R. Dagenais
- Alvaro AvezumAAAlvaro Avezum
- Jan BasileJBJan Basile
- Ignacio CongetICIgnacio Conget
- William C. CushmanWCWilliam C. Cushman
- Mark LakshmananMLMark Lakshmanan
- Fernando LanasFLFernando Lanas
- Lawrence A. LeiterLLLawrence A. Leiter
- Prem PaisPPPrem Pais
- Nana PogosovaNPNana Pogosova
- 20 September 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 24 (10) , 1805-1812
Abstract
Aims: People with diabetes are at high risk for cardiovascular events including heart failure (HF). We examined the effect of the glucagon‐like peptide 1 agonist dulaglutide on incident HF events and other cardiovascular outcomes in those with or without prior HF in the randomized placebo‐controlled Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial. Methods and results: The REWIND major adverse cardiovascular event (MACE) outcome was the first occurrence of a composite endpoint of non‐fatal myocardial infarction, non‐fatal stroke, or death from cardiovascular causes (including unknown causes). In this post‐hoc analysis, a HF event was defined as an adjudication‐confirmed hospitalization or urgent evaluation for HF. Of the 9901 participants studied over a median follow‐up of 5.4 years, 213/4949 (4.3%) randomly assigned to dulaglutide and 226/4952 (4.6%) participants assigned to placebo experienced a HF event (hazard ratio [HR] 0.93, 95% confidence interval [CI] 0.77–1.12; p = 0.456). In the 853 (8.6%) participants with HF at baseline, there was no change in either MACE or HF events with dulaglutide as compared to participants without HF ( p = 0.44 and 0.19 for interaction, respectively). Combined cardiovascular death and HF events were marginally reduced with dulaglutide compared to placebo (HR 0.88, 95% CI 0.78–1.00; p = 0.050) but unchanged in patients with and without HF at baseline ( p = 0.31). Conclusions: Dulaglutide was not associated with a reduction in HF events in patients with type 2 diabetes regardless of baseline HF status over 5.4 years of follow‐up.Keywords
Funding Information
- Eli Lilly and Company
This publication has 28 references indexed in Scilit:
- Design and baseline characteristics of participants in the R esearching cardiovascular E vents with a W eekly IN cretin in D iabetes ( REWIND ) trial on the cardiovascular effects of dulaglutideDiabetes, Obesity and Metabolism, 2017
- GLP-1 receptor agonists and heart failure in diabetesDiabetes & Metabolism, 2017
- Effect of Liraglutide, a Glucagon-Like Peptide-1 Analogue, on Left Ventricular Function in Stable Chronic Heart Failure Patients with and Without Diabetes (LIVE)—a Multicentre, Double-Blind, Randomised, Placebo-Controlled TrialEuropean Journal of Heart Failure, 2016
- Liraglutide and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2016
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary SyndromeNew England Journal of Medicine, 2015
- Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and DeathCirculation, 2015
- Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With AtherothrombosisJAMA, 2010
- Incidence rates of heart failure, stroke, and acute myocardial infarction among Type 2 diabetic patients using insulin glargine and other insulinPharmacoepidemiology and Drug Safety, 2009
- Diabetes and Mortality Following Acute Coronary SyndromesJAMA, 2007
- Congestive Heart Failure in Type 2 DiabetesDiabetes Care, 2001